Express Scripts Holding Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Express Scripts Holding Company
Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma.
Payer concessions to ensure access to drugs during the COVID-19 outbreak offer a benefit to patients and biopharma. But the costs involved could intensify future efforts to manage drug spending.
But declines in other categories held overall spending on US retail pharmacy drugs covered by commercial plans to a marginal 2.3% increase in 2019, Express Scripts reports.
Manufacturers will face the “biggest PBM ever” in price negotiations for pharmacy benefit drugs as a result of the collaboration between the two pharmacy benefit managers.
- Pharmacy Services, PBMs
- Other Names / Subsidiaries
- Aristotle Holding, Inc.
- Cigna Corporation
- Express Scripts, Inc.
- Medco Health Solutions, Inc.